These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2713 related articles for article (PubMed ID: 24332297)

  • 1. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
    Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
    Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and trends in human papillomavirus-related diseases in Central and Eastern Europe and Central Asia.
    Bray F; Lortet-Tieulent J; Znaor A; Brotons M; Poljak M; Arbyn M
    Vaccine; 2013 Dec; 31 Suppl 7():H32-45. PubMed ID: 24332296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
    Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
    Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
    Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Burden of human papillomavirus infections and related diseases in the extended Middle East and North Africa region.
    Vaccarella S; Bruni L; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G32-44. PubMed ID: 24331818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
    Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
    Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations for cervical cancer prevention in Asia Pacific.
    Garland SM; Cuzick J; Domingo EJ; Goldie SJ; Kim YT; Konno R; Parkin DM; Qiao YL; Sankaranarayanan R; Stern PL; Tay SK; Bosch FX
    Vaccine; 2008 Aug; 26 Suppl 12():M89-98. PubMed ID: 18945418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cervical cancer screening, human papillomavirus vaccination practices and current infrastructure in Israel.
    Schejter E; Bornstein J; Siegler E
    Vaccine; 2013 Nov; 31 Suppl 8():I42-5. PubMed ID: 24229718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
    Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
    Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV testing and vaccination in Europe.
    Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
    J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV Vaccination and Cervical Cancer Screening Policies and Practices in 18 Countries, Territories and Entities across Eastern Europe and Central Asia.
    Davies P; Aluloski I; Arifdjanova D; Brcanski J; Davidzenka A; Durdyeva A; Gayrat Umarzoda S; Goshliyev K; Jovanovic V; Jugeli L; Kocinaj-Berisha M; Maistruk G; Naumovic T; Pilav A; Rzayeva G; Saribekyan K; Siljak S; Ten E; Valuta D; Veljkovic M; Yildirimkaya G; Ylli A; Zhylkaidarova A; Melnic E
    Asian Pac J Cancer Prev; 2023 May; 24(5):1781-1788. PubMed ID: 37247301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries.
    Sancho-Garnier H; Khazraji YC; Cherif MH; Mahnane A; Hsairi M; El Shalakamy A; Osgul N; Tuncer M; Jumaan AO; Seoud M
    Vaccine; 2013 Dec; 31 Suppl 6():G51-7. PubMed ID: 24331820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
    Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
    Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementation of human papillomavirus immunization in the developing world.
    Kane MA; Serrano B; de Sanjosé S; Wittet S
    Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global burden of human papillomavirus and related diseases.
    Forman D; de Martel C; Lacey CJ; Soerjomataram I; Lortet-Tieulent J; Bruni L; Vignat J; Ferlay J; Bray F; Plummer M; Franceschi S
    Vaccine; 2012 Nov; 30 Suppl 5():F12-23. PubMed ID: 23199955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of type-specific human papillomavirus infection among women in France: Implications for screening, vaccination, and a future generation of multivalent HPV vaccines.
    Monsonego J; Zerat L; Syrjänen K; Zerat JC; Smith JS; Halfon P
    Vaccine; 2012 Jul; 30(35):5215-21. PubMed ID: 22713720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
    Ginsberg GM
    Vaccine; 2013 Nov; 31 Suppl 8():I46-52. PubMed ID: 24229719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-vaccination prevalence of infections with 25 non-high-risk human papillomavirus types among 1,000 Slovenian women in cervical cancer screening.
    Učakar V; Poljak M; Oštrbenk A; Klavs I
    J Med Virol; 2014 Oct; 86(10):1772-9. PubMed ID: 24978445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 136.